Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is what I surmise, not what I know for sure, but I think the company has been buying back common shares converted from prefrerred shares since early November (when the OS quit growing), and the company will continue to buy back unless and until capital is needed to reestablish (CAH reimbursable) services at Jamestown. Then, the institutional warrant holders start buying them, which won't be for dillution but expansion. That appears to be the strategy, and the numbers work (estimating based on the revenue guidance).
In other words, you are saying the glass is 1/4 empty instead of 3/4 full. We're talking $10 million worth at .0001. Company revenue guidance of $25-30 million just on current services in 2024. Wonderful progress as I see it, but I'm a glass is 3/4 full kind of guy.
Diggity, I don't care about the ticker over the last two years. I don't care about what the ticker is doing today. I plan to take a very large profit on the stock when it is overpriced. Right now the stock is ridiculously undervalued, a no brainer of a buy for those interested in an OTC bargain.
"Just another piece of news?" Longterm restructuring of corporate equity accomplished with a 75% increase in fundemental value (related to the preferred share equity) to common shareholders . Please stop whinning.
The best I can tell (without the advice of a securities lawyer) is that the common share equivilency of the preferred shares was reduced by 75%. And, "certain insitutional warrant holders" have agreed to buy the common shares when (and if) the company needs the money (for new or reopened facilities maybe?), and the company has agreed to buy them back when it determines that it doesn't need the money and can buy them back. Again, that's just my best take without being able to read the terms or without having a securities lawyer to review everything going back to the original preferred share agreements. I can say the CEO is delivering big time on "restructuring debt and other securities" promised in the October 25, 2023 update.
I am right. Buy and hold value. Value always pays.
And INQR pays off that $2.5 million note made by RNVA to INQR. Actually, a (full or partial) repayment of that note may well be part of the "restructuring of debt and other securities" in progress currently.
Not yet. That's the point. If it the price had already corrected (recovered, rebounded, [partially] retraced), we wouldn't be watching it. The current P/E is under 2. Hello?
Not to mention the $2.5 million in debt paid off in 2023 through Q3.
Always.
Current P/E below 2. Historical valuation of OTCs with $20-25 million in revenues and $2-3 million earnings. Many, many examples.
That was a ponzi scheme. RNVA is a hospital and healthcare services provider. I would not have bought RNVA six years ago. The P/L was going in the wrong direction. The last 18 months have been a different story, a legitimate turnaround, CAH certification being a key.
The CEO is an investor too, a big one at that, so I don't get your logic. The CEO didn't oversell and undervalue the stock. The market did.
Minimum 2023 earnings $2 million, probably much higher. That's my estimate, and I'm sticking to it.
More "restructuring of debt and other securities" in progress since early November. Earnings make the world go around.
I'm guessing they'll file a NT 10-K to fold it into an annual report due April 15.
Neither. Read the earnings reports. Also, read past CEO statements to find out if they really were misleading or it's just the whinning of low information lotto traders who speculated as usual about things the CEO didn't say. I've been following RNVA for a couple of years now and have found the CEO updates during that time have understated the positive performance eventually reported.
CAH cost-based reimbursements ensure the cost of services ratio will be in that range or better. Cant ask for much more confidence in an earnings estimate than that.
Pretty simple. The 1/16/24 update says inpatient admissions increased 75% YOY along with growth in new outpatient services. A minimum calculation of the corresponding revenue increase minus the first three quarters yields a Q4 earnings estimate of $.5-2 million on $5-7 million in revenues at a cost of services ratio of 45-50%.
Diggity, I'm just curious. Have you ever watched (so closely) a stock break out of trips from .0001 before?
Dingbatt, RNVA needs more long investors. It's supply and demand, too few investor dollars in OTC chasing too many OTC stocks. It's capitalism that determines how much money comes back to the OTC market and how much stays in overpriced major exchanges where the opposite is true, too many investor dollars chasing too few (big board) stocks. RNVA needs buyers. We don't need to refight the Cold War first.
Not really, at least from a value perspective. Stocks on the big boards are looking pretty expensive. Granted NVDA is on an impressive revenue growth curve, but the P/E was really high the last I looked. Maybe not so high on a forward basis, but just maybe. I would love to spot another overlooked gem like Marvel Enterprises was back when.
I first bought NVDA near the bottom of the crash after the tech bubble. World-class management and stable share structure didn't have much to do with it. It was the P/E around 8 that convinced me NVDA was worth the price. It has been a few years since I have held it. I bought Marvel Enterprises when it was seen on Wall Street as a glorified comic book company. Value.
To each his own trading stragegy, I suppose. Sounds like so much wheelspinning to me. I either buy and hold value, or I don't buy at all.
Might just entice more volume on the accumulation side. Every stock that lifts off .0001 goes through this pattern.
Yep, volume should continue to increase, just beginning to churn. Somebody is accumulating for sure.
I was pretty much a newbe in 1999, so I was oblivious to the regulatory change. Was that legislative, or just some screwed up SEC rule making?
The 2023 P/L is showing a profit through Q3. I agree. RNVA won't sit on .0001 for long.
I think some substantial new long investment is coming to RNVA based on current info. The updates will come when they come.
OTC due a healthy round of bargain hunting as money peels off overpriced stocks on Nasdaq and NYSE. Recent Russell 2000 movement indicates more interest in small caps. Market conditions improving for RNVA.
200 bill MA contingency.
If only $500,000, that's $2 million in earnings for 2023, or a current P/E of 2. I won't sell at a forward P/E much lower than 25.
Not sure what a surprisingly good would mean, but this is my Q4 estimate: "2023 saw inpatient admissions increase by over 75% compared to 2022" (Jan 16 update) Along with other service increases, that translates to Q4 revenues of $5.5-7.5 million. Cost-based CAH reimbursements give us some certainty that the cost of revenues improved with new Myrtle Recovery revenues coming in to around 40-45%, but for the minimum estimate, assume it remained at the 50% reported for Q3. Other expenses being roughly equal or maybe increasing slightly, Q4 earnings were $1-2.5 million.
Wrong again, GeekOfSkidRow. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173906438
Yep. RNVA holds a strong equity position and also made a note to INQR that came due on 12/31 in the amount of $2.5 million. We should hear news on repayment next. Good guess anyway.
.0025/.025/.25 will work for me.
OMG, it doesn't work that way. Those are reputable stock research services that follow reputable analysts. Then there is you.
I passed on some info. You didn't understand it, but you trashed it anyway. It's sort of obvious.
You are the one whinning because I trust reputable sources over you. Sensitive? No, I've just lost my patience for disingenuous BS.